

Labourers' Local 183 Retiree Benefit Trust Fund

MEDICAL CANNABIS PRIOR-AUTHORIZATION Liuna! Local 1 Feel the Power

LiUNAcare Local 183 Email to: info@liunacare183.com

email to: info@liunacare183.com or fax to: 416-240-7488 ATTN: Claims Department

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM Cannabis for Medical Purposes

Please note that the patient AND physician must complete this form. All fields are mandatory and must be completed. Incomplete forms may result in your application being declined. Please retain a copy of this form for your records.

Instructions:

- 1. PLEASE PRINT CLEARLY AND COMPLETE ALL SECTIONS.
- 2. The patient/plan member must complete section A.
- **3.** Your physician must complete section B. The cost, if any, of completing this form is at the expense of the patient/plan member.
- **4.** Please return the form to your insurance company via Pharmacy Services at TELUS Health (a service provider of your insurance company) by fax to **416-240-7488**.
- 5. If you have any questions on the application of this program or the decision on reimbursement, or to inquire on the status of your Reimbursement Request Form, please contact your insurer.

A. Information to be Completed by Patient							
Employee or Member Name	Drug Card Number						
Patient Name	Patient Date of Birth (DD/MMM/YYYY)	Relationship to Employee/Member					
	//	□Employee □Spouse □Dependent					
Please allow two business days for a response once all information is received and complete. Notification of the results of this request will occur Monday to Friday between 9 a.m. and 4 p.m. Eastern Time.							
Please provide contact information and indicate ONE method of preferred contact for notification of the results:							
☐ E-mail me at:	Call me (and leave a message if I'm not there) at:	☐ Fax me at:					
☐ Contact my Licensed Producer/Seller: Licensed Producer/Seller Name:		Licensed Producer/Seller Phone Number:					
I certify that the information provided by me is true, correct and complete to the best of my knowledge. I authorize my insurance company, TELUS Health (a service provider of my insurance company), their authorized representatives, agents and service providers to use and exchange this information needed for underwriting, administration and paying claims with any person or organization who has relevant information pertaining to this claim including health professionals, institutions and investigative agencies in the event of an audit. I authorize my insurance company and/or TELUS Health (a service provider of my insurance company) to contact any licensed physician, institution, licensed producer/seller or person who has any records or knowledge of me or my health with respect to this submitted claim.							
SIGNATURE OF PATIENT/PARENT/LEGAL GUARDIAN							
Date: (DD/MMM/YYYY):/	/						

LiUNAcare Local 183 Email to: info@liunacare183.com

or fax to: 416-240-7488
ATTN: Claims Department

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM Cannabis for Medical Purposes

B. Information to be Completed by Prescribing Physician

Drug Name	Strength	Dose				
Cannabis						
Cannabis will be eligible for reimbursement only if the patient satisfies the conditions listed below and if the patient does not qualify for coverage under any other drug plan or government mandated program. If the patient is covered under another drug plan or government mandated program, the prior authorization program, as part of your drug benefits, may cover the portion not paid for by the primary plan. If "None of the above criteria" is indicated, the patient will not be eligible for reimbursement. For Quebec plan members, please refer to the RAMQ exception drug criteria, if applicable.						
Eligibility Criteria						
Please indicate if the patient satisfies the following criteria	<u> </u>					
, , , , , , , , , , , , , , , , , , ,	•					
☐ Chronic Pain						
Inclusion criteria (approval period of 12 weeks): Patient:						
Has refractory neuropathic pain, OR						
Has refractory neuropathic pain association						
☐ Is currently receiving optimize	ed antiretroviral therapy, AND					
 Is ≥ 18 years of age, AND Has had a reasonable therapeutic trial (6 weeks) of ≥ 3 prescribed analgesics (including as appropriate but not limited to gabapentin, pregabalin, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, and topical capsaicin) and has persistent problematic pain despite optimized analgesic 						
therapy, AND Has had a reasonable trial (6 weeks) of nabilone or nabiximols (e.g., Sativex) in combination with analgesic therapies and has persistent problematic pain despite optimized analgesic therapy in combination with nabilone or nabiximols, AND						
Cannabis will be used as an adjunct to other pre						
Prescriber is a specialist in the management of c	hronic pain or HIV-associated ne	europathy				
☐ Renewal Criteria (approval period of 1 year)						
☐ A 12 week trial of cannabis has demonstrated	efficacy based on:					
Improved analgesia by 2 or more poinImproved functioning	ts on a 10-point scale, AND					
OR						
☐ Palliative Care (approval period of 1 year)						
Patient: ☐ Is ≥ 18 years of age, AND						
Requires palliative (end-of-life) cancer pain r	nanagement, AND					
\Box Has had a reasonable therapeutic trial of ≥ 2		ersistent problematic pain				
despite optimized analgesic therapy, AND						
☐ Has had a reasonable trial of nabilone in com						
problematic pain despite optimized analgesic Cannabis will be used as an adjunct to other pre		bitorie, AND				
Prescriber is an oncologist or experienced in the use of cannabis in palliative care						

OR

Patient:

Spasticity (approval period of 1 year)

 \Box Is ≥ 18 years of age, AND

LiUNAcare Local 183 Email to: info@liunacare183.com

or fax to: 416-240-7488 ATTN: Claims Department

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM Cannabis for Medical Purposes

Eligibility Criteria

Address

rny	rsician's Name	License Number	Telephone Number	Fax Number			
Physician Information							
	weight loss, AND Prescriber is an oncologist or e	experienced in the	e use of cannabis for cancer, pallia	tive care or HIV/AIDS			
	☐ Has had a reasonable therapeutic trial (6 weeks) with nabilone and continues to experience involuntary						
	□ Has had a reasonable therapeutic trial of ≥ 1 standard therapies including but not limited to progesterone analogues, corticosteroids, and dietary counselling and continues to experience involuntary weight loss, AND						
	□ Is currently receiving highly active antiretroviral therapy, AND □ Is \geq 18 years of age, AND						
		for anorexia-cach	nexia associated with HIV/AIDS, AN	ND.			
	Anorexia-Cachexia (approval perio Patient:						
	OR						
	☐ Prescriber is an oncologist or is	otherwise experi	ienced in the use of cannabis in th	e management of CINV			
	are not limited to s (aprepitant, fosapro (prochlorperazine, i	erotonin antagoni epitant), corticost metoclopramide),	es and has persistent CINV. Standa sts (e.g., ondansetron), neurokinin teroids (dexamethasone), and dopa AND tle) of nabilone and has persistent	n-1 receptor antagonists amine antagonists			
	If receiving highly e	metogenic chemo	tle) of nabilone and has persistent otherapy, has had a reasonable the	erapeutic trial (1 cycle)			
	CINV. Standard therapies include but are not limited to serotonin antagonists (eg. ondansetron), neurokinin-1 receptor antagonists (aprepitant, fosaprepitant), corticosteroids (dexamethasone), and dopamine antagonists (prochlorperazine, metoclopramide), AND						
	 Requires management of refractory CINV, AND Has had a reasonable therapeutic trial (2 cycles total) involving ≥ 2 standard therapies and has persistent 						
	Patient: \square Is \ge 18 years of age, AND						
	Chemotherapy-Induced Nausea and	Vomiting (CINV) (approval period of 1 year)				
	OR						
	Cannabis will be used as anPrescriber is a neurologist or is spasticity		prescribed standard therapies, AN ienced in the use of cannabis in th				
	spasticity, AND	,	eks) of nabiximols (e.g., Sativex) a	•			
	pharmaceutical measures (s spasticity despite optimized	such as daily stret I standard therap	ching, range-of-movement exercisies, AND	ses) and has persistent			
	 □ Requires treatment for spasticity due to Multiple Sclerosis OR Spinal Cord Injury, AND □ Has had a reasonable therapeutic trial (6 weeks) of ≥ 2 standard therapies (including but not limited to baclofen, gabapentin, tizanidine, dantrolene, benzodiazepine, or botulinum toxin), and non- 						
	Requires treatment for spas	ticity due to Mult	tiple Sclerosis OR Spinal Cord Injur	y, AND			

City

Province

Postal Code

LiUNAcare Local 183 Email to: info@liunacare183.com

or fax to: 416-240-7488 ATTN: Claims Department

PRIOR AUTHORIZATION PROGRAM REIMBURSEMENT REQUEST FORM Cannabis for Medical Purposes

Eligibility Criteria	
Physician's Signature	Date: (DD/MMM/YYYY)
	///